When should thyroid peroxidase (TPO) antibody testing be ordered?

When to Order TPO Antibody Testing

TPO antibody testing should be ordered in patients with subclinical hypothyroidism, recurrent miscarriage, suspected autoimmune thyroiditis with nodular disease, and in pregnant women with prior Graves' disease treated with radioiodine or thyroidectomy. 1

Primary Indications for TPO Testing

Subclinical Hypothyroidism

• Order TPO antibodies when evaluating any patient with subclinical hypothyroidism (elevated TSH with normal free T4) to predict progression to overt disease 1
• TPO-positive patients progress to overt hypothyroidism at 4.3% per year versus 2.6% per year in TPO-negative patients 1, 2, 3
• The presence of positive TPO antibodies helps stratify risk and guides monitoring frequency, though it may not always change the immediate treatment decision 1

Pregnancy-Related Scenarios

• Measure TPO antibodies in women with recurrent miscarriage, with or without infertility, as thyroid autoimmunity is associated with poor obstetric outcomes 1
• Test pregnant women with a history of Graves' disease treated with radioiodine or thyroidectomy (though this specifically requires TSH receptor antibodies, not TPO) 1
• Women planning pregnancy who are TPO-positive should be monitored closely, as they have increased risk of first-trimester hypothyroidism and postpartum thyroiditis 4, 5

Nodular Thyroid Disease

• Order TPO antibodies when nodular thyroid disease is suspected to be due to autoimmune thyroiditis rather than non-immunologic multinodular goiter 1
• This distinction is clinically important because the nodular variant of autoimmune thyroiditis carries significant risk of progression to hypothyroidism, whereas simple multinodular goiter rarely destroys functioning tissue 1
• In patients with a diffuse, firm goiter, TPO measurement identifies autoimmune thyroiditis and may guide the need for fine-needle aspiration 1

Secondary Indications in High-Risk Populations

Patients with Other Autoimmune Conditions

• Consider TPO testing in patients with type 1 diabetes mellitus, Addison's disease, Down syndrome, or Turner syndrome to assess risk of developing hypothyroidism 1, 2
• These populations have substantially elevated baseline risk for thyroid autoimmunity 1

Drug-Induced Risk

• Measure TPO antibodies in patients starting lithium, interferon-alpha, amiodarone, or tyrosine kinase inhibitors to provide prognostic information about hypothyroidism risk 1, 4
• TPO-positive patients on these medications require more frequent thyroid function monitoring 4

When NOT to Order TPO Testing

Established Hypothyroidism

• Do not order TPO antibodies in patients with already-confirmed overt hypothyroidism (low free T4), as the result does not alter management 2
• TPO testing confirms autoimmune etiology but does not change the treatment algorithm for overt disease 2

Routine Screening

• TPO antibodies should not be ordered as a screening test in asymptomatic, euthyroid individuals without risk factors 2
• The presence of isolated TPO positivity in euthyroid patients does not warrant treatment, only monitoring 2

Diagnosis of Hypothyroidism

• Never use TPO antibodies alone to diagnose hypothyroidism—always confirm thyroid dysfunction with TSH and free T4 first 2, 6
• TPO testing is a prognostic and etiologic tool, not a diagnostic one for thyroid dysfunction 1

Clinical Interpretation Pearls

Understanding TPO Prevalence

• Approximately 75% of patients with chronic autoimmune thyroiditis have detectable TPO antibodies 2
• However, 8-12% of the general euthyroid population also has positive TPO antibodies 4, 3
• TPO antibodies tend to persist once present; spontaneous disappearance is uncommon 2

Correlation with TSH

• Even within the normal TSH range, TPO antibody titers correlate with TSH levels, suggesting subclinical thyroid dysfunction 4, 3
• Patients with high-normal TSH (2.5-5.49 mIU/L) have 18.6% TPO positivity versus 3% in those with low-normal TSH (0.36-2.49 mIU/L) 7

Monitoring Strategy

• Euthyroid patients with positive TPO antibodies require TSH monitoring every 6-12 months due to the 4.3% annual progression risk 2
• Educate TPO-positive patients about hypothyroidism symptoms (fatigue, cold intolerance, weight gain) to facilitate early detection between visits 2

Common Pitfalls to Avoid

• Do not initiate levothyroxine therapy based solely on positive TPO antibodies in euthyroid patients—treatment requires documented thyroid dysfunction 2
• Avoid ordering TPO antibodies in patients already on levothyroxine for established hypothyroidism, as the result provides no actionable information 2
• Remember that a single elevated TSH may be transient—repeat testing after 2 weeks to 3 months before ordering TPO antibodies 2
• Do not confuse TPO antibodies with TSH receptor antibodies (TRAb)—the latter are needed for Graves' disease diagnosis and fetal risk assessment in pregnancy 1, 8